Helius Medical Technologies Inc logo

HSM - Helius Medical Technologies Inc Share Price

C$0.81 0.1  6.6%

Last Trade - 22/05/20

Sector
Healthcare
Size
Micro Cap
Market Cap £17.8m
Enterprise Value £14.2m
Revenue £844k
Position in Universe 1009th / 2658
Bullish
Bearish
Unlock HSM Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Helius Medical Technologies Inc revenues decreased 69% to $207K. Net loss totaled $4.8M vs. income of $1.3M. Revenues reflect License revenue decrease of 99% to $7K. Net loss reflects Change in fair value of derivative finan decrease of 100% to $4K (income), Foreign exchange gain (loss) increase from $155K to $765K (expense), Other (expense) income decrease of 45% to $6K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HSM Revenue Unlock HSM Revenue

Net Income

HSM Net Income Unlock HSM Revenue

Normalised EPS

HSM Normalised EPS Unlock HSM Revenue

PE Ratio Range

HSM PE Ratio Range Unlock HSM Revenue

Dividend Yield Range

HSM Dividend Yield Range Unlock HSM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HSM EPS Forecasts Unlock HSM Revenue
Profile Summary

Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company’s offered product is portable neuromodulation stimulator (PoNS) device. PoNS is an authorized class II, non-implantable, medical device in Canada intended for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
No. of Shareholders: 61
No. of Employees: 19
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Toronto Stock Exchange
Shares in Issue 38,041,666
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HSM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.